Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Handheld Ultrasound Evaluation of the Inferior Vena Cava to Guide Heart Failure Treatment

4. juni 2018 opdateret af: Jagat Narula, Icahn School of Medicine at Mount Sinai

A Randomized Study of Pocket Ultrasound Derived IVC Diameter for Guided Management of Heart Failure

The purpose of this study is to see if using a portable handheld ultrasound to guide diuretic therapy for heart failure patients will prevent hospital readmissions. This study will use a handheld ultrasound called a Vscan to look at a large vessel in the body called the Inferior Vena Cava (a vein leading to your heart) . The study aims to see whether changing diuretic therapy based on the size of this vessel will result in the less hospitalizations for heart failure patients as compared to just symptom guided therapy. This study is composed of two independent non-interacting trials-one in the outpatient setting and one in the inpatient setting.

Studieoversigt

Status

Afsluttet

Betingelser

Detaljeret beskrivelse

The purpose of this research study is to investigate the use of pocket ultrasound device, called Vscan, in guiding diuretic therapy in ambulatory and inpatient Congestive Heart Failure (CHF) patients. Specifically, Vscan will be used to monitor Inferior Vena Cava (IVC) diameters with the goal of reaching a 50% reduction in IVC when compared to baseline measurements. We hypothesize that compared to the conventional clinical assessment Guided Diuretic Therapy, this new proposed Vscan guided therapy will result in reduction in hospitalization rates. This study is composed of two independent non-interacting randomized single blinded trials-one in the outpatient setting and one in the inpatient setting. 138 total patients and 300 patients will be recruited to the ambulatory trial and inpatient trial respectively.

  1. Objectives The objective of the study is to determine whether a simple one step protocol of increasing diuretics to guide a 50% reduction of IVC diameter from baseline measurements results in reduction in hospitalization rates as compared to those seen in therapy determined on the basis of conventional clinical evaluation by a CHF specialist.
  2. Background Congestive heart failure (CHF) remains a leading cause of death in industrialized countries. Despite advances in medical treatment, an estimated 250,000-300,000 CHF patients are hospitalized in the United States each year for symptoms caused by low cardiac output (CO). Although the events that cause acute decompensation are multifactorial, the common pathway associated with decreased ventricular function are autonomic dysfunction and fluid retention. It has been previously suggested that an estimated 50%-66% of CHF hospitalizations may be preventable with improved monitoring of fluid volume status. The size and shape of the inferior vena cava (IVC) is correlated to the central venous pressure and circulating blood volume. Therefore evaluation of the IVC provides an instantaneous non-invasive measure of volume status.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

37

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10029
        • Icahn School of Medicine at Mount Sinai

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with a diagnosis of congestive heart failure
  • NYHA class II-IV (ambulatory only)
  • left ventricular systolic dysfunction with ejection fraction (EF) < 50%
  • history of hospitalization for heart failure within the last year (ambulatory only)
  • age >18 years old
  • admission to heart failure service (inpatient arm only)

Exclusion Criteria:

  • Patients with dyspnea not mainly due to heart failure
  • valvular disease requiring surgery
  • acute coronary syndromes within the previous 10 days
  • revascularization within the previous month
  • body mass index higher than 35
  • serum creatinine level higher than 2.49 mg/dL
  • a life expectancy of less than 3 years from noncardiovascular diseases (ambulatory arm only)
  • a life expectancy of less than 1 year from noncardiovascular disease (inpatient arm only)
  • non-cardiovascular causes of acute renal failure present on admission that preclude the use of diuretics (inpatient arm only)
  • unable to give informed consent
  • no follow-up possible
  • participating in another study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Handheld ultrasound - inpatient
Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
Handheld ultrasound determination of IVC diameter
Andre navne:
  • VSCAN
  • Handheld Ultrasound IVC Diameter Guided Diuretic Therapy
Sham-komparator: Sham ultrasound - inpatient
Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
sham ultrasound to facilitate blinding
Andre navne:
  • Conventional Symptom Guided Diuretic Therapy
Eksperimentel: Handheld ultrasound - ambulatory
Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
Handheld ultrasound determination of IVC diameter
Andre navne:
  • VSCAN
  • Handheld Ultrasound IVC Diameter Guided Diuretic Therapy
Sham-komparator: Sham ultrasound - ambulatory
Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
sham ultrasound to facilitate blinding
Andre navne:
  • Conventional Symptom Guided Diuretic Therapy

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants Hospitalized for Cardiovascular Reasons
Tidsramme: up to 6 months
hospitalization information will be recorded throughout the length of the study for the outpatient arms
up to 6 months
Number of Participants Hospitalized for Non-cardiac Reasons
Tidsramme: up to 6 months
hospitalization information will be recorded throughout the length of the study for the inpatient arms
up to 6 months
Diuretic Change Post-visit
Tidsramme: 6 months followup
Differences in Changes made in Diuretic doses after Heart failure related visit
6 months followup

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants in Each New York Heart Association Class
Tidsramme: 6 months

New York Heart Association (NYHA) Classification Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.

Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.

Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100m). Comfortable only at rest.

Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

6 months
Change in Health Related Quality of Life
Tidsramme: 1 month and 6 months
Change in Health related quality of life at 6 months as compared to at 1 month
1 month and 6 months
Length of Stay
Tidsramme: up to 6 months
length of stay in the hospital for inpatient arms only
up to 6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Jagat Narula, MD, PhD, Icahn School of Medicine at Mount Sinai

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. august 2013

Primær færdiggørelse (Faktiske)

1. december 2015

Studieafslutning (Faktiske)

1. december 2015

Datoer for studieregistrering

Først indsendt

10. oktober 2013

Først indsendt, der opfyldte QC-kriterier

10. oktober 2013

Først opslået (Skøn)

14. oktober 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. juni 2018

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. juni 2018

Sidst verificeret

1. juni 2018

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • GCO 13-0324
  • IF1486768 (Anden identifikator: Mount Sinai)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner